# Omeros Corporation (OMER)

Source: https://www.quantisnow.com/company/OMER
Generated: 2026-11-18T10:11:56.322Z

- Ticker: OMER
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2009
- SEC CIK: 0001285819
- Website: omeros.com

## About

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

## Latest OMER news and filings

- 2026-11-16 21:10 UTC [SEC Form 8-K] [Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/omeros-corporation-filed-sec-form-8-k-results-of-operations-and-6794114)
- 2026-11-16 21:02 UTC [Earnings] [Omeros Corporation Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/omeros-corporation-reports-third-quarter-2026-financial-results-6793876)
- 2026-11-10 21:02 UTC [Earnings Date] [Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026](https://www.quantisnow.com/insight/omeros-corporation-to-announce-third-quarter-financial-results-on-november-6783756)
- 2026-10-30 21:04 UTC [SEC Form 4] [Chairman, CEO & President Demopulos Gregory A Md was granted 500,000 performance stock options (SEC Form 4)](https://www.quantisnow.com/insight/chairman-ceo-president-demopulos-gregory-a-md-was-granted-500000-6765539)
- 2026-10-30 21:01 UTC [SEC Form 8-K] [Omeros Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/omeros-corporation-filed-sec-form-8-k-leadership-update-financial-statements-6765528)
- 2026-10-16 10:19 UTC [Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA](https://www.quantisnow.com/insight/omeros-corporation-receives-chmp-negative-opinion-following-re-examination-of-european-6748602)
- 2026-09-25 01:00 UTC [SEC Form 4] [VP, Finance & CAO Borges David J. exercised 20,000 shares at a strike of $9.51 and sold $419,000 worth of shares (20,000 units at $20.95) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/vp-finance-cao-borges-david-j-exercised-20000-shares-at-6725875)
- 2026-09-22 12:28 UTC [Analyst Upgrade] [Omeros upgraded by Cantor Fitzgerald with a new price target](https://www.quantisnow.com/insight/omeros-upgraded-by-cantor-fitzgerald-with-a-new-price-target-6722498)
- 2026-09-01 20:41 UTC [SEC Form 4] [VP, General Counsel Cancelmo Peter B exercised 50,000 shares at a strike of $2.94 and sold $929,668 worth of shares (50,000 units at $18.59) (SEC Form 4)](https://www.quantisnow.com/insight/vp-general-counsel-cancelmo-peter-b-exercised-50000-shares-at-6701646)
- 2026-08-28 20:31 UTC [SEC Form 4] [Director Hanish Arnold C sold $282,094 worth of shares (15,000 units at $18.81) and exercised 15,000 shares at a strike of $15.23 (SEC Form 4)](https://www.quantisnow.com/insight/director-hanish-arnold-c-sold-282094-worth-of-shares-15000-6698532)
- 2026-08-27 20:12 UTC [SEC Form 144] [SEC Form 144 filed by Omeros Corporation](https://www.quantisnow.com/insight/sec-form-144-filed-by-omeros-corporation-6697156)
- 2026-08-26 20:16 UTC [SEC Form 144] [SEC Form 144 filed by Omeros Corporation](https://www.quantisnow.com/insight/sec-form-144-filed-by-omeros-corporation-6695688)
- 2026-08-25 21:40 UTC [SEC Form 4] [VP, Finance & CAO Borges David J. exercised 10,906 shares at a strike of $3.48 and sold $206,805 worth of shares (10,906 units at $18.96) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/vp-finance-cao-borges-david-j-exercised-10906-shares-at-6694667)
- 2026-08-21 21:34 UTC [SEC Form 4] [Director Cable Thomas J. sold $276,772 worth of shares (15,000 units at $18.45) and exercised 15,000 shares at a strike of $2.96 (SEC Form 4)](https://www.quantisnow.com/insight/director-cable-thomas-j-sold-276772-worth-of-shares-15000-6691755)
- 2026-08-19 01:51 UTC [SEC Form 4] [SEC Form 4 filed by Director Schocken Joseph L](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-schocken-joseph-l-6687577)
- 2026-08-19 01:44 UTC [SEC Form 3] [New insider Schocken Joseph L claimed ownership of 528,082 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-schocken-joseph-l-claimed-ownership-of-528082-shares-6687575)
- 2026-08-17 23:42 UTC [SEC Form 4] [VP, Finance & CAO Borges David J. exercised 5,000 shares at a strike of $3.93 and sold $84,750 worth of shares (5,000 units at $16.95) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/vp-finance-cao-borges-david-j-exercised-5000-shares-at-6685632)
- 2026-08-13 20:06 UTC [SEC Form S-8] [SEC Form S-8 filed by Omeros Corporation](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-omeros-corporation-6680343)
- 2026-08-13 20:05 UTC [SEC Form 8-K] [Omeros Corporation filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/omeros-corporation-filed-sec-form-8-k-leadership-update-6680333)
- 2026-08-12 20:12 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Omeros Corporation](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-omeros-corporation-6677950)
- 2026-08-12 20:09 UTC [SEC Form 8-K] [Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/omeros-corporation-filed-sec-form-8-k-results-of-operations-and-6677915)
- 2026-08-12 20:02 UTC [Earnings Date] [Omeros Corporation Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/omeros-corporation-reports-second-quarter-2026-financial-results-6677672)
- 2026-08-10 12:00 UTC [Earnings Date] [Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026](https://www.quantisnow.com/insight/omeros-corporation-to-announce-second-quarter-financial-results-on-august-6672794)
- 2026-08-03 12:30 UTC [CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®](https://www.quantisnow.com/insight/cms-grants-new-technology-add-on-payment-ntap-status-to-yartemlea-6658870)
- 2026-07-25 01:17 UTC [SEC Form 4] [SEC Form 4 filed by Chairman, CEO & President Demopulos Gregory A Md](https://www.quantisnow.com/insight/sec-form-4-filed-by-chairman-ceo-president-demopulos-gregory-6648747)
- 2026-07-25 01:13 UTC [SEC Form 4] [SEC Form 4 filed by VP, General Counsel Cancelmo Peter B](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-general-counsel-cancelmo-peter-6648744)
- 2026-07-25 01:11 UTC [SEC Form 4] [SEC Form 4 filed by VP, Finance & CAO Borges David J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-vp-finance-cao-borges-david-6648743)
- 2026-07-20 21:05 UTC [SEC Form 8-K] [Omeros Corporation filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/omeros-corporation-filed-sec-form-8-k-other-events-6642727)
- 2026-07-06 12:30 UTC [SEC Form 8-K] [Omeros Corporation filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/omeros-corporation-filed-sec-form-8-k-other-events-6627431)
- 2026-06-26 12:30 UTC [Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA](https://www.quantisnow.com/insight/omeros-corporation-announces-update-on-european-marketing-authorization-application-for-6616783)
- 2026-06-25 10:02 UTC [SEC Form 8-K] [Omeros Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/omeros-corporation-filed-sec-form-8-k-submission-of-matters-to-6614962)
- 2026-06-22 11:35 UTC [SEC Form 4] [SEC Form 4 filed by Director Shah Rajiv](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-shah-rajiv-6610004)
- 2026-06-22 11:34 UTC [SEC Form 4] [SEC Form 4 filed by Director Perkinson Diana T.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-perkinson-diana-t-6610003)
- 2026-06-22 11:34 UTC [SEC Form 4] [SEC Form 4 filed by Director Hood Leroy E. Md Phd](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hood-leroy-e-md-6610001)
- 2026-06-22 11:33 UTC [SEC Form 4] [SEC Form 4 filed by Director Hanish Arnold C](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hanish-arnold-c-6610000)
- 2026-06-22 11:33 UTC [SEC Form 4] [SEC Form 4 filed by Director Demopulos Peter A Md](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-demopulos-peter-a-md-6609999)
- 2026-06-22 11:32 UTC [SEC Form 4] [SEC Form 4 filed by Director Cable Thomas J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cable-thomas-j-6609998)
- 2026-06-22 11:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Bumol Thomas F.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bumol-thomas-f-6609996)
- 2026-06-18 11:52 UTC [SEC Form 8-K] [Omeros Corporation filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/omeros-corporation-filed-sec-form-8-k-other-events-6607884)
- 2026-06-15 12:30 UTC [Omeros Announces Webcast Details for Annual Meeting of Shareholders](https://www.quantisnow.com/insight/omeros-announces-webcast-details-for-annual-meeting-of-shareholders-6602016)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OMER
- Earnings history: https://www.quantisnow.com/earnings/OMER
- Dividend history: https://www.quantisnow.com/dividends/OMER
- Insider transactions: https://www.quantisnow.com/insiders/OMER
- Options chain: https://www.quantisnow.com/options/OMER
- SEC 8-K filings only: https://www.quantisnow.com/company/OMER/8-k
- RSS and alerts for OMER: https://www.quantisnow.com/docs/rss-feeds.md
